Concurrent molecular alterations in KRAS-mutant lung adenocarcinomas and effects on overall survival.

8033 Background: KRAS mutations define the largest subset of oncogene-driven lung adenocarcinomas (25-30%). Among patients with KRAS mutations, their clinical course during treatment is heterogeneous. The presence of concurrent genetic alterations in other oncogenes and tumor suppressors, such as TP53 or STK11 may affect outcomes for patients with KRAS mutant lung cancers. We sought to use a next-generation sequencing-based assay to comprehensively describe concurrent genetic alterations present in KRAS mutant lung cancers and explore the effect of such alterations on patient outcomes. Methods: We studied tumor DNAs from 102 patients with stage IV/recurrent KRAS mutant lung cancers enriched for cases with longer and shorter overall survivals. All patients received standard therapies for advanced lung cancer. We performed massively parallel sequencing (Ion Torrent PGM) of all exons from 65 cancer genes using a custom AmpliSeq panel. The sequence data were analyzed for point mutations and small insertions a...